<p>Voglibose is used in diabetes mellitus (DM) for reduction in Post-Prandial Hyperglycaemia (PPHG), only when diet and/or exercise with lifestyle modification or Oral Hypoglycaemic Agents (OHAs) or insulin preparations, in addition to diet and/or exercise, do not result in an adequate glycaemic control.<br />
<br />
Thus, Voglibose is indicated:</p>

<ul>
	<li>In non-insulin-dependent diabetes mellitus (NIDDM) patients as immunotherapy</li>
	<li>In combination with other OHAs</li>
	<li>In addition to insulin in diabetes mellitus patients</li>
	<li>In prevention of onset of type 2 diabetes mellitus in impaired glucose tolerance (only for Voglibose 0.2 mg Tablets) (However, Voglibose&nbsp;Tablets should be used only when impaired glucose tolerance has not been improved in patients already undergoing appropriate dietary treatment and/or exercise therapy.)</li>
	<li>In elderly patients and in those with hepatic dysfunction or mild to moderate renal impairments in whom other OHAs are contraindicated or they need to be used with caution, Voglibose will be helpful.</li>
	<li>In glycogen storage disease: Voglibose is helpful in prevention of hypoglycaemia in patients with type lb glycogen storage disease, it being an amylase (a glucosidase) inhibitor.</li>
	<li>In non-diabetic Hyperinsulinemia, Voglibose is helpful in preventing hypoglycaemic attacks.</li>
	<li>In steroid induced diabetes mellitus also, Voglibose is helpful. However, clinical data in this setting are limited.</li>
</ul>